Our technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. We are developing our lead product candidate REQORSA to be administered with targeted therapies and with immunotherapies for NSCLC and SCLC. We continue to conduct preclinical research to explore how REQORSA may be administered with targeted therapies and immunotherapies in other solid tumors, and we are researching how other cancer fighting genes can enhance our portfolio using our non-viral gene therapy platform, the ONCOPREX Nanoparticle Delivery System. Using a different gene therapy delivery system, we are also developing our pre-clinical diabetes candidates, GPX-002 and GPX-003. The following table summarizes our product development pipeline as of November 14, 2023 (the filing of our Quarterly Report on Form 10-Q).

Tagrisso® is a registered trademark of AstraZeneca.

Keytruda® is a registered trademark of Merck.

Tarceva® is a registered trademark of Astellas and the Roche Group of companies.